Summary
53 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It could repay all its net debt from 0.9 years of operating profit.
What to watch
- Revenue growth is slowing: 4.3% a year over the last 3 years against 13% over 5 years.
- Out of every 100 USD of revenue, only 3.9 USD is left as net profit.
- It earns only 5.2 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 23.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 4.3% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 64 USD
- Sales and administration 31 USD
- Taxes and other 1.2 USD
- Net profit 3.9 USD
Net profit, industry median (Medical - Care Facilities) 6.7 USD
Out of every 100 USD of revenue, 3.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.